Pyrimidine Derivative for Inflammation Treatment

The USPTO published patent application US20260092044A1 disclosing a pyrimidine derivative compound of formula (I) as an mPGES-1 inhibitor for pharmaceutical use. The compound (R represents methyl group or fluorine atom) is intended for prophylactic and/or therapeutic treatment of inflammation, pain, or rheumatism. The application classifies under CPC C07D 401/04 and names ASKA Pharmaceutical Co., Ltd. as assignee.

This is a patent application publication, not a regulatory action imposing obligations. Pharmaceutical companies and researchers developing mPGES-1 inhibitors should review the application to assess potential freedom-to-operate implications for their own compounds. No compliance deadlines or regulatory actions apply to this document.